Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyz...
Data could not be retrieved
NURO | Peers | Sector | |
---|---|---|---|
Market Cap | 9.09 M | 52.07 M | 66.093 M |
Price % of 52 Week High | Premium | 60.4% | 63.0% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | Premium | -1.5% | -0.7% |
1 Year Price Total Return | 9.1% | -10.8% | -11.5% |
Beta (5 Year) | 2.17 | 1.57 | 0.64 |
10Y DCF Revenue ExitView Updated 1 day ago |
5Y DCF Revenue ExitView Updated 1 day ago |
DuPont ROE AnalysisView Updated 1 day ago |
10Y Historical FinancialsView Updated 1 day ago |
5Y Historical FinancialsView Updated 1 day ago |
EV / EBIT MultiplesView Updated 1 day ago |
P/E MultiplesView Updated 1 day ago |
Price / Book MultiplesView Updated 1 day ago |
Price / Sales MultiplesView Updated 1 day ago |
EV / Revenue MultiplesView Updated 1 day ago |
10Y DCF EBITDA ExitView Updated 1 day ago |
10Y DCF Growth ExitView Updated 1 day ago |
5Y DCF EBITDA ExitView Updated 1 day ago |
5Y DCF Growth ExitView Updated 1 day ago |
Earnings Power ValueView Updated 1 day ago |
EV / EBITDA MultiplesView Updated 1 day ago |
CAPM WACC ModelView Updated 5 hours ago |
(USD in millions) | Trailing Twelve Months | Fiscal Quarters | |||
---|---|---|---|---|---|
Period Ending | Dec-22 | Dec-23 | Sep-24 | Sep-23 | Sep-24 |
Income Statement | |||||
Revenue | 8.26 | 5.90 | 3.77 | 1.20 | 0.59 |
Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
EBITDA | |||||
Balance Sheet | |||||
Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Debt | 0.36 | 0.24 | 0.14 | 0.27 | 0.14 |
Cash Flow Statement | |||||
Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Free Cash Flow | (5.31) | (6.27) | (6.73) | (2.20) | (1.79) |